{"id":"sulfonylurea-non-sulfonylurea-insulin-secretagogues","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL328697","moleculeType":"Small molecule","molecularWeight":"621.78"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They work by binding to sulfonylurea receptors on the surface of beta cells, which leads to closure of ATP-sensitive potassium channels and depolarization of the cell membrane. This results in opening of voltage-dependent calcium channels, influx of calcium ions, and subsequent release of insulin from secretory granules.","oneSentence":"Sulfonylurea/non-sulfonylurea insulin secretagogues stimulate insulin release from pancreatic beta cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:43.600Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT03421119","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2019-06-20","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT01077323","phase":"","title":"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)","enrollment":363766},{"nctId":"NCT00732524","phase":"PHASE4","title":"Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2004-09","conditions":"Type 2 Diabetes","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sulfonylurea or non-sulfonylurea insulin secretagogues"],"phase":"phase_3","status":"active","brandName":"Sulfonylurea/non-sulfonylurea insulin secretagogues","genericName":"Sulfonylurea/non-sulfonylurea insulin secretagogues","companyName":"Cinnagen","companyId":"cinnagen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulfonylurea/non-sulfonylurea insulin secretagogues stimulate insulin release from pancreatic beta cells. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}